loader image
Coptotes
  • PEACH AND BLUEBERRY COMPOTE

    100% NATURAL PRODUCT!

    The combination of useful substances for the organism, the fruit of peach and blueberry impact very favorably on the body. The combination of these two has a variety of fruit astringent, anti-inflammatory, anti-diabetic, anti- inflammatory, hemostatic, antibacterial, diuretic and choleretic properties. Compote is recommended to drink chilled.

  • QUINCE COMPOTE

    100% NATURAL PRODUCT!

    Quince compote is made from good ripe quince. In quince have provitamin A , vitamin B , C, E, PP , a number of other trace elements. Potassium quince is10 times higher than sodium . Quince is rich in malic and citric acids. There are also a lot of pectins and tartronic acid.

    Quince compote strengthens the body , acts as an anti -inflammatory, astringent and diuretic. It is recommended to drink at the problems of the gastrointestinal tract , anemia, heart disease and respiratory diseases.

  • PEACH COMPOTE

    100% NATURAL PRODUCT!

    Peach compote contains organic acids: malic, tartaric, citric , mineral salts of elements such as potassium , iron , phosphorus , manganese , copper , zinc , selenium, and magnesium. It is rich in vitamin complex : vitamin C, vitamin B, E , K, PP , and carotene. The composition of peach compote also includes pectin and essential oils.

    Peach compote enhances the secretory activity of the stomach , improves digestion of fatty foods, has useful properties for such ailments as gout , rheumatism, kidney disease.

  • FEIJOA COMPOTE

    100% NATURAL PRODUCT!

    Fruit feijoa contains vitamins (B1 , B2 , B3 , B5 , B6 , PP ), micro – and macroelements (iodine , calcium, potassium, sodium, magnesium, phosphorus, iron , copper , zinc, manganese) , acids ( malic acid, folic ) and essential oils with aroma of pineapple and strawberries. Due to the presence in the fruit pulp of digestible protein and fat feijoa relates to dietary foods , using which you can replace one of the meals or it can beused in dishes for diet . This will compensate for the lack of vitamins and reduce weight.

    Feijoa fruit doctors prescribe to people with disorders of the thyroid gland and mental stress. Also it is used in the treatment and prevention of diseases such as inflammation of the digestive tract, gastritis, atherosclerosis, vitamin deficiency, vitamin deficiencies, pyelonephritis, gout, Graves’ disease, and constipation.

MAKE A STEP TOWADS TO

LONGEVITY!

GET IN TOUCH WITH US

     

    Global Longevity Disclaimer

    Potentially interested parties should note that participation in the Global Longevity project is subject to limitations imposed by applicable securities laws in various jurisdictions.

    Potential investors should note that participation in the Global Longevity Sale is subject to limitations imposed by applicable securities laws in various jurisdictions. The following does neither constitute an offer to buy or to subscribe for the Potentially interested parties should note that participation in the Global Longevity project is subject to limitations imposed by applicable securities laws in various jurisdictions.

    Potential investors should note that participation in the Global Longevity project Sale is subject to limitations imposed by applicable securities laws in various jurisdictions. The following does neither constitute an offer to buy or to subscribe for the Global Longevity project. Investors should make their decision to buy or to subscribe to Global Longevity project.

    Investors are furthermore advised to consult their bank or financial adviser before making any investment decision. This publication may contain specific forward-looking statements, e.g. statements including terms like “believe”, assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements.

    Against the background of these uncertainties, readers should not rely on forward-looking statements. Global Longevity project assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

    The Global Longevity project are not for sale and distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any state of the United States and the District of Columbia), Canada, Japan, Australia, North Korea, Iran, Myanmar, Afghanistan, Angola, Aruba, Bangladesh, Belarus, Benin, Bhutan, Bolivia, Botswana, Brunei Darussalam, Burkina Faso, Bosnia, Burundi, Cambodia, Cameroon, Cape Verde, Central Africa republic, Chad, Comorros, Congo, Congo Democratic republic, Cuba, Cote d’Ivoire, Djibouti, Dominica, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guatemala, Guyana, Guinea, Guinea Bissau, Haiti, Honduras, Iraq, Jordan, Kenya, Kyrgyz Republic, Laos People’s Republic, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Micronesia, Moldova, Mongolia, Mozambique, Nauru, Nepal, New Caledonia, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palestinian Areas, Papua New Guinea, Reunion, Rwanda, Samoa, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, South Georgia, Sudan, Sri Lanka, Suriname, Syria, Swaziland, Tajikistan, Tanzania, Timor, Togo, Tonga, Tunisia, Turkmenistan, Uganda, Uzbekistan, Venezuela, Western Sahara, Yemen, Zambia, Zimbabwe or any jurisdiction into which the same would be unlawful.

    This announcement does not constitute or form a part of any offer or solicitation to purchase, subscribe for or otherwise acquire securities in the United States, Canada, Japan, Australia, North Korea, Iran, Myanmar,Afghanistan, Angola, Aruba, Bangladesh, Belarus, Benin, Bhutan, Bolivia, Botswana, Brunei Darussalam, Burkina Faso, Bosnia, Burundi, Cambodia, Cameroon, Cape Verde,Central Africa republic, Chad, Comorros, Congo, Congo Democratic republic, Cuba, Cote d’Ivoire, Djibouti, Dominica, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guatemala, Guyana, Guinea, Guinea Bissau, Haiti, Honduras, Iraq, Jordan, Kenya, Kyrgyz Republic, Laos People’s Republic, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Micronesia, Moldova, Mongolia, Mozambique, Nauru, Nepal, New Caledonia, Nicaragua, Niger, Nigeria, Niue, Oman, Pakistan, Palestinian Areas, Papua New Guinea, Reunion, Rwanda, Samoa, Sao Tome and Principe, Senegal, Sierra Leone, Somalia, South Georgia, Sudan, Sri Lanka, Suriname, Syria, Swaziland, Tajikistan, Tanzania, Timor, Togo, Tonga, Tunisia, Turkmenistan, Uganda, Uzbekistan, Venezuela, Western Sahara, Yemen, Zambia, Zimbabwe or any jurisdiction in which such an offer or solicitation is unlawful.

    The Global Longevity project will not be registered under the US Securities Act of 1933, as amended or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, within the United States.

    The Global Longevity project have not been approved or disapproved by the US Securities and Exchange Commission, any state’s securities commission in the United States or any US regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of the Global Longevity project or the accuracy or adequacy of this announcement. Any representation to the contrary is a criminal offence in the United States. The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom.

    This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Global Longevity project are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such the Global Longevity project will be engaged in only with, relevant persons.

    Any person who is not a relevant person should not act or rely on this document or any of its contents. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.